The MOPETT Trial took sub-massive PE patients and randomized them to half-dose tPA vs. standard care. No bleeds in either group. 41% ARR of pulmonary hypertension at 28 months.
Study Description from the Author
Does this change your game?
A new trial using a similar protocol showed benefit without complications (Clinical Cardiology Volume 37, Issue 2, pages 78–82, February 2014)
Latest posts by Scott Weingart (see all)
- EMCrit Wee – First Study of the Benefits of an EDICU - September 10, 2019
- EMCrit – The Pigtail Video - September 4, 2019
- EMCrit 255 – Pigtails for Pleural Problems (Percutaneous Thoracostomy) - September 4, 2019